Skip to Content
Merck
  • A fast and sensitive quantitative lateral flow immunoassay for Cry1Ab based on a novel signal amplification conjugate.

A fast and sensitive quantitative lateral flow immunoassay for Cry1Ab based on a novel signal amplification conjugate.

Sensors (Basel, Switzerland) (2012-11-01)
Chunxiang Chen, Jian Wu
ABSTRACT

A novel lateral flow immunoassay (LFIA) signal amplification strategy for the detection of Cry1Ab based on amplification via a polylysine (PL) chain and biotin-streptavidin system (BSAS) is described. In this system, multiple fluorescence dyes (FL) were directly coated on the surface of PL and conjugated with antibody via the BSAS for construction of novel signal amplification (FLPL-BSAS-mAb1) conjugates, in which FL, PL and BSAS were employed to improve the sensitivity of LFIA. Compared with conventional LFIA, the sensitivity of FLPL-BSAS-mAb1-based LFIA was increased by approximately 100-fold. Quantified linearity was achieved in the value range of 0-1,000 pg/mL. The limit of detection (LOD) was reached 10 pg/mL after optimization of reaction conditions. To our knowledge, this represents one of the most sensitive LFIA for Cry1Ab yet reported. Furthermore, the detection time for this method was about 10 min. Therefore, it should be an attractive alternative compared to conventional immunoassays in routine control for Cry1Ab.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Atto 647N azide, BioReagent, suitable for fluorescence
Sigma-Aldrich
Atto 647N amine, BioReagent, suitable for fluorescence
Supelco
Atto 647N maleimide, BioReagent, suitable for fluorescence, ≥90% (HPLC)
Sigma-Aldrich
Atto 647N-Biotin, BioReagent, suitable for fluorescence, ≥90.0% (HPLC)
Sigma-Aldrich
Atto 647N NHS ester, BioReagent, suitable for fluorescence, ≥90% (HPLC)
Supelco
Atto 647N, BioReagent, suitable for fluorescence, ≥90.0% (HPLC)